BML Inc (JP:4694)
:4694
Want to see JP:4694 full AI Analyst Report?
Top Page
BML
(4694)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥3,648.00
▼(-4.38% Downside)
Action:Downgraded
Date:05/15/26
The score is primarily supported by strong financial stability (low leverage) and a constructive recent rebound in earnings/cash flow, but is held back by clearly weak technical momentum (below major moving averages, negative MACD) and only moderate valuation support despite a solid dividend yield.
Positive Factors
Strong Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility. This solvency allows the company to fund R&D, capex or acquisitions, absorb cyclical shocks and avoid refinancing stress, supporting long-term stability and strategic optionality.
Negative Factors
Revenue & Margin Volatility
Significant multi-year volatility in sales and margins reduces predictability of earnings and planning. Structural demand swings or competitive pressures that caused earlier declines could re-emerge, limiting visibility for investment decisions and long-term margin recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Balance Sheet
Very low leverage and a large equity base provide durable financial flexibility. This solvency allows the company to fund R&D, capex or acquisitions, absorb cyclical shocks and avoid refinancing stress, supporting long-term stability and strategic optionality.
Read all positive factors
BML (4694) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥131.82B
Dividend Yield3.34%
Average Volume (3M)54.09K
Price to Earnings (P/E)19.9
Beta (1Y)0.40
Revenue Growth4.94%
EPS Growth26.92%
CountryJP
Employees4,513
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)164.55
Shares Outstanding40,749,428
10 Day Avg. Volume38,460
30 Day Avg. Volume54,093
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)1.21
Price to Sales (P/S)1.02
P/FCF Ratio12.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥4,500.00Price Target Upside17.96% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)222.3
Revenue Forecast (FY)¥157.00B
BML Business Overview & Revenue Model
Company Description
BML, Inc. provides laboratory testing and related services in Japan. The company offers general laboratory tests, including biochemical and hematologic examinations; special laboratory tests, such as RIA, cellular, immunological, and DNA analysis;...
How the Company Makes Money
null...
BML Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
88
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 145.63B | 150.26B | 143.19B | 137.96B | 159.46B | 186.07B |
| Gross Profit | 46.42B | 48.69B | 45.86B | 45.63B | 61.45B | 86.95B |
| EBITDA | 17.84B | 19.54B | 17.08B | 15.96B | 30.29B | 54.78B |
| Net Income | 6.42B | 7.75B | 6.26B | 6.04B | 15.58B | 33.74B |
Balance Sheet | ||||||
| Total Assets | 175.54B | 183.25B | 177.99B | 171.46B | 169.27B | 179.59B |
| Cash, Cash Equivalents and Short-Term Investments | 65.46B | 68.03B | 67.56B | 74.11B | 86.52B | 92.13B |
| Total Debt | 4.29B | 4.82B | 5.29B | 5.26B | 4.16B | 3.35B |
| Total Liabilities | 42.81B | 51.12B | 44.21B | 41.32B | 42.52B | 57.91B |
| Stockholders Equity | 128.46B | 127.67B | 129.40B | 125.87B | 122.49B | 116.20B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 11.96B | 663.00M | -4.57B | 7.18B | 39.91B |
| Operating Cash Flow | 0.00 | 20.71B | 15.81B | 14.45B | 11.74B | 45.60B |
| Investing Cash Flow | 0.00 | -7.69B | -16.79B | -21.14B | -7.63B | -7.30B |
| Financing Cash Flow | 0.00 | -12.35B | -5.43B | -5.73B | -9.71B | -9.83B |
BML Technical Analysis
Negative
3815.00
Price Trends
4032.27
Negative
3910.31
Negative
3686.78
Positive
Market Momentum
-26.43
Positive
36.61
Neutral
7.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4694, the sentiment is Negative. The current price of 3815 is below the 20-day moving average (MA) of 4011.48, below the 50-day MA of 4032.27, and above the 200-day MA of 3686.78, indicating a neutral trend. The MACD of -26.43 indicates Positive momentum. The RSI at 36.61 is Neutral, neither overbought nor oversold. The STOCH value of 7.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4694.
BML Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ¥131.82B | 19.87 | 5.94% | 3.34% | 4.94% | 26.92% | |
55 Neutral | ¥93.76B | 27.16 | ― | 2.31% | 3.35% | 74.40% | |
54 Neutral | ¥137.64B | -14.40 | ― | 2.18% | -10.48% | -1022.09% | |
53 Neutral | ¥50.79B | 12.89 | ― | 2.79% | 0.34% | -7.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥122.04B | 279.88 | 2.42% | 3.73% | 0.78% | -95.37% |
* Healthcare Sector Average
JP:4694
BML
3,525.00
683.46
24.05%
JP:6523
PHC Holdings Corp.
963.00
49.06
5.37%
JP:2395
Shin Nippon Biomedical Laboratories, Ltd.
1,220.00
-33.80
-2.70%
JP:4549
Eiken Chemical Co., Ltd.
2,844.00
871.39
44.17%
JP:4974
Takara Bio Inc.
1,143.00
362.00
46.35%
BML Corporate Events
BML Reshapes Top Management as Representative Director Retires
May 13, 2026
BML, Inc. announced that Representative Director and Vice-President Nobuki Arai will retire from his role as Representative Director when his term as Director expires on June 26, 2026, while continuing in key positions at PCL Japan, Inc. and BML G...
BML Raises Year-End Dividend After Beating Earnings Forecasts
May 13, 2026
BML, Inc. has approved an increase in its year-end dividend for the fiscal year ended March 31, 2026, raising the payout to 65 yen per share from the previously forecast 60 yen. The total annual dividend for FY2026 will be 125 yen per share, up fr...
BML lifts earnings and dividend on solid FY2025 results, guides cautiously for FY2026
May 13, 2026
BML, Inc. reported solid results for the fiscal year ended March 31, 2026, with net sales rising 4.9% to ¥150.3 billion and profit attributable to owners of parent climbing 23.7% to ¥7.7 billion, lifting basic earnings per share to ¥...
BML Reshapes Leadership to Bolster Genome and Medical IT Businesses
Mar 30, 2026
BML, Inc. has announced a series of senior management and organizational changes approved by its Board of Directors on March 30, 2026, reflecting a strategic emphasis on genome-related services and systems operations. Representative Director and V...
BML Revises First-Quarter 2024 Earnings Data After Discovering Numerical Errors
Mar 16, 2026
BML, Inc. has announced corrections to its consolidated earnings report for the first quarter of fiscal 2024 under Japanese GAAP, after discovering errors in previously disclosed numerical data. The revisions mainly affect the company’s repo...
BML Corrects Third-Quarter 2024 Balance Sheet Figures and Equity Ratio
Mar 16, 2026
BML, Inc., a Japan-based clinical testing and diagnostic services provider listed on the Tokyo Prime Market, has issued a correction to its previously disclosed consolidated earnings report for the third quarter of fiscal 2024. The revision update...
BML Corrects Fiscal 2024 Earnings Report, Adjusts Asset and Profitability Ratios
Mar 16, 2026
BML, Inc. has announced corrections to its previously released consolidated earnings report for fiscal 2024, identifying and amending errors discovered after the original disclosure in May 2025. The revisions affect key profitability and balance s...
BML Revises First-Quarter FY2025 Balance-Sheet Figures, Lowers Reported Equity Ratio
Mar 16, 2026
BML, Inc. has corrected previously disclosed figures in its consolidated earnings report for the first quarter of fiscal 2025, released on August 8, 2025, after identifying errors in its financial position data. The revisions primarily affect repo...
BML Revises First-Half Fiscal 2025 Balance Sheet Figures After Data Errors
Mar 16, 2026
BML, Inc. announced it has corrected errors in its previously released consolidated earnings report for the first six months of fiscal 2025, adjusting key balance sheet figures while keeping equity capital unchanged. The revised data show total as...
BML Revises Third-Quarter Fiscal 2025 Balance Sheet Figures
Mar 16, 2026
BML, Inc. has corrected previously disclosed figures in its consolidated earnings report for the third quarter of fiscal 2025, revising total assets upward while leaving net assets unchanged. The company reported that total assets as of December 3...
BML Restates Five Years of Filings Over Retirement Benefit Accounting Error
Mar 16, 2026
BML, Inc. has submitted correction reports for past annual, semi-annual and quarterly securities filings, along with related earnings reports, after discovering errors in the accounting treatment of retirement benefit assets and liabilities. The c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.